I'm applying independent scoring across five dimensions for each article, noting where I diverge from the Phase 1 triage scores. Several Phase 1 scores reflect over-generous triage (e.g., a retrospective miRNA study in a neurology journal scored 9 under a "Precision oncology" topic) — I correct these.

Key corrections and notes:

• Article 1 (PMID 42667237): Triage score of 9 with evidence_maturity = "Potentially Practice-Changing" is a significant over-call. This is a retrospective cohort of 270 patients studying a miRNA in stroke + sleep apnea — misclassified under precision oncology. No practice-changing evidence present.
• Study design labels: Many articles are labeled "Randomized Controlled Trial (inferred)" when they are clearly retrospective cohort studies, reviews, or protocols. I score based on actual design.
• Non-human studies: Clinical Relevance capped at 5 per rules.
• Title-only / low-confidence records: Scored conservatively throughout.
• "Mixed" species models are treated as human-applicable where the data are clearly human.

---

Article-by-Article Scoring

---

Article 1 — Liu et al. (PMID 42667237): miR-486-3p in ACI + OSAS

Dimension	Score	Notes
Scientific Novelty	4	miRNA biomarker work in stroke+OSAS is incremental; miR-486-3p not a new target
Clinical Relevance	4	Retrospective cohort, 270 pts; biomarker not validated for clinical use
Population Reach	5	ACI+OSAS comorbidity is common, but biomarker is far from clinical use
Implementation Speed	2	Needs prospective validation; years from any application
Evidence Strength	4	Retrospective cohort; single center implied; abstract only

• Key quantitative result: Stratified AHI groups (mild/mod/severe) — specific effect sizes not reported in abstract.
• External validation: None.
• Main limitation: Retrospective design, single institution, small severe OSAS subgroup (n=35), abstract-only access.
• Equity: No data on underrepresented groups; study from China — generalizability unclear.
• Evidence Maturity (revised): Exploratory (OpenClaw said "Potentially Practice-Changing" — this is incorrect for a single retrospective study)
• OpenClaw triage_score: 9 | Phase 2 composite: 3.9

---

Article 2 — Lee (PMID 42667695): AI ECG Decision Support

Dimension	Score	Notes
Scientific Novelty	5	Dual-stream ECG deep learning is incremental; multiple commercial systems exist
Clinical Relevance	6	ECG AI is actively being deployed; head-to-head with commercial benchmark is relevant
Population Reach	8	ECG interpretation affects essentially all patients in acute care settings globally
Implementation Speed	5	Modular design helps; still needs regulatory approval and clinical validation
Evidence Strength	4	Study design unclear from abstract; single-author paper; no sample size reported

• Key quantitative result: Claims superiority over commercial standards — no specific AUC/sensitivity figures in abstract.
• External validation: Not reported.
• Main limitation: Abstract-only; single author raises concerns; no blinded clinical comparison described.
• Equity: Modular design for resource-limited settings is a meaningful equity consideration.
• Evidence Maturity (revised): Exploratory (not "Potentially Practice-Changing" without validated performance data)
• OpenClaw triage_score: 8 | Phase 2 composite: 5.8

---

Article 3 — Wang et al. (PMID 42667563): AI in PSMA-PET for Prostate Cancer (Review)

Dimension	Score	Notes
Scientific Novelty	5	Active and growing field; review synthesizes existing work rather than generating new data
Clinical Relevance	6	PSMA-PET is now standard for PCa staging; AI integration has direct workflow implications
Population Reach	7	Prostate cancer: ~1.5M new cases/year globally; PSMA-PET access expanding rapidly
Implementation Speed	4	Translation requires regulatory pathways and multicenter validation
Evidence Strength	3	Narrative review; no primary data; "Exploratory" maturity appropriate

• Key quantitative result: None (review).
• External validation: N/A.
• Main limitation: Review only; cannot confirm performance claims; heterogeneous PSMA expression not resolved.
• Equity: Access to PSMA-PET itself remains limited in LMICs — AI benefits may compound existing inequity.
• Evidence Maturity (revised): Exploratory (confirmed)
• OpenClaw triage_score: 8 | Phase 2 composite: 5.3

---

Article 4 — Chalewska et al. (PMID 42667809): PET QC Standardization (Review)

Dimension	Score	Notes
Scientific Novelty	3	QC and harmonization in PET is well-established; incremental review
Clinical Relevance	5	Important for reproducibility of SUV-based decisions; indirect patient impact
Population Reach	6	All oncology patients receiving PET globally
Implementation Speed	6	Intrinsic QC methods are already available; adoption depends on institutional uptake
Evidence Strength	3	Review only; no new primary data

• Key quantitative result: None stated.
• Main limitation: Review; no comparative efficacy data for proposed QC methods.
• Equity: Standardization could reduce inter-site variability and benefit patients at lower-resourced centers.
• Evidence Maturity (revised): Exploratory (confirmed)
• OpenClaw triage_score: 8 | Phase 2 composite: 4.7

---

Article 5 — Karim et al. (PMID 42667489): Circadian Clocks and Cancer (Review)

Dimension	Score	Notes
Scientific Novelty	6	Circadian oncology is a genuinely emerging field with growing mechanistic clarity
Clinical Relevance	3	No clinical application ready; review of mechanisms only
Population Reach	5	All cancers potentially affected but no actionable intervention described
Implementation Speed	1	Pre-clinical concept; 10+ years from clinical translation
Evidence Strength	3	Narrative review; no primary data

• Key quantitative result: None.
• Main limitation: Review only; circadian-targeted therapy not yet clinically validated.
• Equity: Chronotherapy could disproportionately benefit patients who cannot tolerate standard regimens.
• Evidence Maturity (revised): Exploratory (confirmed)
• OpenClaw triage_score: 8 | Phase 2 composite: 3.6

---

Article 6 — Dalle et al. (PMID 42667537): Adjuvant Nivolumab in Melanoma (AdjuMel, 2-Year Real-World)

Dimension	Score	Notes
Scientific Novelty	4	Nivolumab adjuvant is already approved/standard; real-world data adds context, not novelty
Clinical Relevance	7	2-year real-world data from France informs tolerability, adherence, and effectiveness vs. trial
Population Reach	6	Stage III-IV resected melanoma: ~25,000 new cases/year in EU+US combined
Implementation Speed	7	Drug already approved; data immediately applicable to practice
Evidence Strength	5	Prospective observational (not RCT); French cohort; abstract-only; no efficacy outcomes reported yet

• Key quantitative result: Not reported in abstract (2-year interim).
• External validation: CheckMate 238 RCT provides trial basis.
• Main limitation: Observational design; no comparator arm; abstract-only; outcomes data incomplete.
• Equity: French cohort — limited generalizability to lower-income countries with restricted access.
• Evidence Maturity (revised): Validated (real-world validation of approved therapy)
• OpenClaw triage_score: 8 | Phase 2 composite: 5.8

---

Article 7 — Luo et al. (PMID 42668074): Antidiabetic Medications and Cancer Prognosis (Meta-Analysis, 61 studies, >1.1M patients)

Dimension	Score	Notes
Scientific Novelty	6	Large-scale synthesis of antidiabetic drug effects on cancer prognosis is genuinely novel in scope
Clinical Relevance	7	Millions of cancer patients have T2DM; knowing if metformin/GLP-1/SGLT2 helps or harms matters
Population Reach	9	T2DM + cancer comorbidity affects tens of millions globally
Implementation Speed	4	Hypothesis-generating by authors' own admission; prospective confirmation needed
Evidence Strength	5	Systematic review/meta-analysis but heterogeneous observational studies; confounding uncontrolled

• Key quantitative result: Heterogeneous associations across 7 drug classes — specific HRs not in abstract.
• External validation: Meta-analytic design pools existing studies; no new validation.
• Main limitation: Authors explicitly state findings are hypothesis-generating; confounding by indication is severe.
• Equity: Patients in LMICs with cancer + T2DM often have limited drug options — findings could be misapplied without prospective data.
• Evidence Maturity (revised): Exploratory (confirmed — authors' own caveat)
• OpenClaw triage_score: 8 | Phase 2 composite: 6.4

---

Article 8 — Moreno-Cabañas et al. (PMID 42668015): Grape Seed Extract + Exercise, BP in Cardiometabolic Risk (RCT)

Dimension	Score	Notes
Scientific Novelty	4	GSE is a well-studied supplement; combining with exercise is incremental
Clinical Relevance	4	BP management question is relevant but effect sizes likely small; abstract absent
Population Reach	6	Cardiometabolic risk is a huge population but effect size needed to assess relevance
Implementation Speed	5	Supplement + exercise is low-barrier but requires demonstration of meaningful benefit
Evidence Strength	6	Double-blind crossover RCT is strong design; labeled "exploratory" by authors

• Key quantitative result: Not reported in abstract (NCT number only).
• Main limitation: Exploratory crossover trial; likely small sample; abstract-only.
• Equity: Low-cost supplement if effective could benefit lower-income populations.
• Evidence Maturity (revised): Exploratory (despite RCT design, explicitly exploratory)
• OpenClaw triage_score: 8 | Phase 2 composite: 4.8

---

Article 9 — Majee et al. (PMID 42667658): Early-Onset SLE with Discoid Rash and Chondritis (Case Report)

Dimension	Score	Notes
Scientific Novelty	4	Atypical jSLE presentation; adds to case literature but no new mechanism
Clinical Relevance	5	High clinical suspicion message is relevant for pediatric rheumatology practice
Population Reach	4	jSLE is rare; ~1-2/100,000 children; relevant to a narrow specialty population
Implementation Speed	5	Clinical awareness message is immediately applicable
Evidence Strength	2	Case report/unspecified design; single case

• Key quantitative result: None.
• Main limitation: Single case; no generalizability.
• Equity: jSLE disproportionately affects girls of African and Asian descent — diagnostic delays are an equity issue.
• Evidence Maturity (revised): Exploratory (confirmed)
• OpenClaw triage_score: 8 | Phase 2 composite: 4.1

---

Article 10 — Schouten et al. (PMID 42668260): Historical Data in RCT Design (Bayesian Power Prior)

Dimension	Score	Notes
Scientific Novelty	5	Bayesian historical control methods are not new, but data-driven τ estimation is a practical advance
Clinical Relevance	6	Could meaningfully reduce sample sizes in confirmatory trials, speeding drug development
Population Reach	7	Methodological advance affects all clinical trial domains
Implementation Speed	5	Statisticians can adopt relatively quickly; regulatory acceptance is the main barrier
Evidence Strength	6	Applied methods paper with validation example; peer-reviewed in Clinical Trials

• Key quantitative result: Data-driven τ estimation substantially increased effective sample size without altering treatment effect estimates.
• Main limitation: Demonstration in one setting; regulatory acceptance for primary outcomes unclear; abstract-only.
• Equity: Smaller trials are particularly relevant for rare diseases and LMIC contexts.
• Evidence Maturity (revised): Validated (confirmed — methodological validation study)
• OpenClaw triage_score: 8 | Phase 2 composite: 5.9

---

Article 11 — Verhagen et al. (PMID 42668119): Real-World HCC Management in Netherlands (5-Year Multicenter Prospective)

Dimension	Score	Notes
Scientific Novelty	5	Real-world practice pattern analysis; confirms guideline gaps rather than generating new science
Clinical Relevance	6	Guideline adherence data in HCC is directly relevant to quality improvement
Population Reach	6	HCC: ~900,000 new cases/year globally; Netherlands data generalizable to high-income countries
Implementation Speed	7	Findings immediately applicable to guideline revision and QI efforts
Evidence Strength	6	5-year prospective multicenter cohort; strong for practice pattern research

• Key quantitative result: Real-world treatment frequently deviates from EASL guidelines.
• Main limitation: Single-country (Netherlands); abstract-only; no survival outcomes reported.
• Equity: Guideline deviation may be more common in under-resourced centers, a finding with equity relevance.
• Evidence Maturity (revised): Validated (confirmed)
• OpenClaw triage_score: 8 | Phase 2 composite: 6.1

---

Article 12 — Ozawa et al. (PMID 42667896): Prevascular Mediastinal Nodules Diagnostic Review

Dimension	Score	Notes
Scientific Novelty	4	Integrative review of existing imaging + clinical data; no new data
Clinical Relevance	6	Incidentally detected mediastinal nodules are increasingly common with CT utilization
Population Reach	5	Relevant to chest radiologists and thoracic surgeons
Implementation Speed	5	Diagnostic algorithm immediately applicable if adopted
Evidence Strength	3	Review only; no primary data

• Evidence Maturity (revised): Exploratory (confirmed)
• OpenClaw triage_score: 7 | Phase 2 composite: 4.9

---

Article 13 — Rahmani et al. (PMID 42667848): THBS1/VEGFA Ratio in AML Stratification

Dimension	Score	Notes
Scientific Novelty	6	THBS1/VEGFA ratio as a transcriptomic stratifier in AML is a genuinely novel framing
Clinical Relevance	5	AML stratification beyond cytogenetics is clinically important; tool needs prospective validation
Population Reach	5	AML: ~20,000 new cases/year in US; relevant to a defined high-need population
Implementation Speed	4	Transcriptomic ratio needs prospective validation before clinical use
Evidence Strength	4	Observational cohort; abstract-only; sample size and validation cohort not reported

• Key quantitative result: THBS1/VEGFA ratio stratifies AML beyond cytogenetic risk categories.
• Main limitation: No prospective validation; abstract-only; unknown sample size.
• Equity: AML disproportionately affects older adults; better stratification could reduce over/undertreatment.
• Evidence Maturity (revised): Exploratory (OpenClaw said "Validated" — insufficient for that label without validation cohort)
• OpenClaw triage_score: 7 | Phase 2 composite: 4.9

---

Article 14 — Barraud et al. (PMID 42667736): Waldenström's Macroglobulinemia in ICU (Retrospective Multicenter)

Dimension	Score	Notes
Scientific Novelty	4	First multicenter description of WM in ICU — fills a genuine data gap
Clinical Relevance	6	Directly applicable to ICU oncology management of WM
Population Reach	3	WM is rare (~1,500 new cases/year in US); ICU subset is very small
Implementation Speed	6	SOFA score + autoimmune cytopenia predictors are immediately usable for risk stratification
Evidence Strength	5	Multicenter retrospective; abstract-only; no sample size

• Key quantitative result: SOFA score and autoimmune cytopenias most associated with ICU mortality.
• Main limitation: Retrospective; small numbers expected given disease rarity; selection bias.
• Equity: Rare disease — equity dimension relates to access to specialized hematology-ICU expertise.
• Evidence Maturity (revised): Validated (confirmed — provides first multicenter descriptive validation)
• OpenClaw triage_score: 7 | Phase 2 composite: 4.7

---

Article 15 — Abramson et al. (PMID 42667569): BV + Nivolumab + Limited Chemo in Early-Stage cHL (Phase 2 Summary)

Dimension	Score	Notes
Scientific Novelty	5	Phase 2 data for chemotherapy-sparing approach in cHL is clinically relevant
Clinical Relevance	7	Reducing chemotherapy burden in early-stage cHL is a meaningful clinical goal
Population Reach	5	Classical HL ~9,000 cases/year in US; early-stage nonbulky is a subset
Implementation Speed	5	Phase 2 only; Phase 3 needed for standard-of-care adoption
Evidence Strength	6	Phase 2 clinical trial (SGN35-027); summary publication format; abstract-only

• Key quantitative result: Results support BV + nivolumab + limited chemo in nonbulky early-stage cHL.
• Main limitation: Phase 2 only; no OS data; summary article format.
• Equity: Younger patients (HL peak incidence 20s-30s) stand to gain most from reduced long-term toxicity.
• Evidence Maturity (revised): Validated (Phase 2 trial — confirmed)
• OpenClaw triage_score: 7 | Phase 2 composite: 5.8

---

Article 16 — Scheichel et al. (PMID 42667447): CST Response in PCNS-LBCL (Multicenter Cohort)

Dimension	Score	Notes
Scientific Novelty	5	Corticosteroid sensitivity in PCNS lymphoma as a prognostic factor is a known phenomenon; this adds multicenter quantification
Clinical Relevance	6	Prognostic value of CST response could guide biopsy timing and management
Population Reach	3	PCNSL is rare; ~1,500 cases/year in US
Implementation Speed	6	Radiological response assessment is already part of workup — findings immediately applicable
Evidence Strength	5	Multicenter observational; abstract-only; sample size unknown

• Evidence Maturity (revised): Validated (confirmed)
• OpenClaw triage_score: 7 | Phase 2 composite: 5.0

---

Article 17 — Williams et al. (PMID 42666617): Perioperative MIBC Treatment in Immunotherapy Era (Review)

Dimension	Score	Notes
Scientific Novelty	5	Review of evolving perioperative immunotherapy in MIBC; timely and clinically relevant synthesis
Clinical Relevance	7	MIBC perioperative management is actively changing with new approvals
Population Reach	6	Bladder cancer: ~85,000 new cases/year in US; MIBC is ~25%
Implementation Speed	5	Review synthesizes trial data; implementation depends on approval and access
Evidence Strength	3	Narrative review; no primary data

• Evidence Maturity (revised): Exploratory (confirmed)
• OpenClaw triage_score: 7 | Phase 2 composite: 5.3

---

Article 18 — Thomas & Soto (PMID 42667959): AI in Thyroid Disease (Review)

Dimension	Score	Notes
Scientific Novelty	4	Comprehensive review across many AI+thyroid applications; breadth over depth
Clinical Relevance	6	Thyroid nodule evaluation is a high-volume problem where AI could reduce unnecessary biopsies
Population Reach	8	Thyroid nodules extremely common; thyroid cancer ~45,000 cases/year in US
Implementation Speed	5	Some AI tools for thyroid US already commercially available; broader deployment ongoing
Evidence Strength	3	Narrative review; no primary data

• Evidence Maturity (revised): Exploratory (confirmed)
• OpenClaw triage_score: 7 | Phase 2 composite: 5.5

---

Article 19 — Yin et al. (PMID 42666552): LLM + RAG for Glaucoma Clinical Reasoning

Dimension	Score	Notes
Scientific Novelty	6	RAG-augmented LLM for ophthalmology-specific clinical reasoning is novel and methodologically interesting
Clinical Relevance	5	Glaucoma management decisions require nuanced judgment; LLM safety issues are directly relevant
Population Reach	6	Glaucoma affects ~80M people globally; specialist shortages make decision support relevant
Implementation Speed	5	LLMs are deployable quickly but safety validation needed before clinical use
Evidence Strength	5	Observational study with retrospective cases; abstract-only

• Evidence Maturity (revised): Validated (for performance characterization — confirmed)
• OpenClaw triage_score: 7 | Phase 2 composite: 5.5

---

Article 20 — Williams & Weiss (PMID 42667265): Adjuvant CDK4/6 Inhibitors in Early Breast Cancer (Review)

Dimension	Score	Notes
Scientific Novelty	5	CDK4/6 inhibitors in adjuvant breast cancer are the subject of intense ongoing debate (monarchE, PALLAS, PENELOPE-B, NATALEE)
Clinical Relevance	8	Directly relevant to one of the most common treatment decisions in oncology
Population Reach	9	HR+/HER2- breast cancer is the most common breast cancer subtype globally
Implementation Speed	7	Abemaciclib adjuvant already approved; ribociclib approval recent; review informs immediate practice
Evidence Strength	4	Review only; but synthesizes multiple RCTs

• Key quantitative result: Review integrates monarchE, NATALEE data showing improved iDFS; OS data maturing.
• Main limitation: Review; individual patient-level benefit estimation remains uncertain; toxicity and cost not fully addressed.
• Equity: CDK4/6 inhibitors are expensive; access disparities are significant globally.
• Evidence Maturity (revised): Validated (review of validated trial data — OpenClaw said "Exploratory" which undersells it)
• OpenClaw triage_score: 7 | Phase 2 composite: 6.7

---

Article 21 — Jiang et al. (PMID 42667576): PD-1 Rechallenge in Older NSCLC Patients (Retrospective, Single-Center)

Dimension	Score	Notes
Scientific Novelty	5	PD-1 rechallenge is under-studied in the elderly; adds to a sparse literature
Clinical Relevance	6	Older NSCLC patients are often excluded from trials; real-world data is needed
Population Reach	7	NSCLC is the leading cause of cancer death; elderly patients are a majority
Implementation Speed	4	Single-center; preliminary — needs multicenter validation
Evidence Strength	3	Single-center retrospective; small sample (not reported); acknowledged selection bias

• Evidence Maturity (revised): Exploratory (OpenClaw said "Validated" — this single-center retrospective does not meet that bar)
• OpenClaw triage_score: 7 | Phase 2 composite: 5.1

---

Article 22 — Duan et al. (PMID 42667570): T-DXd in Chinese HER2-Mutant NSCLC (RERUN Protocol)

Dimension	Score	Notes
Scientific Novelty	5	T-DXd in HER2-mutant NSCLC is already validated; Chinese real-world data fills a gap
Clinical Relevance	7	Real-world data on T-DXd in Chinese patients will directly inform practice in the world's largest oncology market
Population Reach	7	NSCLC in China is a massive public health issue; HER2-mutant ~3% of cases but still large numbers
Implementation Speed	4	Protocol publication — data not yet available
Evidence Strength	3	Protocol paper only; no results reported

• Main limitation: Protocol publication — no results available.
• Equity: Directly addresses a real-world equity gap for Chinese patients.
• Evidence Maturity (revised): Exploratory (protocol only — OpenClaw "Validated" is incorrect)
• OpenClaw triage_score: 7 | Phase 2 composite: 5.4

---

Article 23 — Conte et al. (PMID 42668238): FAMILY Study — Cardiac CT in Asymptomatic FH of MI

Dimension	Score	Notes
Scientific Novelty	6	Specifically targeting FH of premature CAD with cardiac CT and genomics is well-framed
Clinical Relevance	7	Family history is underutilized in CV risk stratification; CT findings could change management
Population Reach	7	Millions have family history of premature CAD and are currently missed by standard scoring
Implementation Speed	4	Study design paper; awaiting full enrollment and results
Evidence Strength	4	Feasibility/design paper; preliminary cohort only

• Evidence Maturity (revised): Exploratory (design paper, not "Potentially Practice-Changing")
• OpenClaw triage_score: 7 | Phase 2 composite: 5.9

---

Article 24 — Gorantla et al. (PMID 42668063): National Health Systems and Lung Cancer Mortality

Dimension	Score	Notes
Scientific Novelty	5	Health system determinants of cancer outcomes is an established research area; this provides global scope
Clinical Relevance	5	Important for health policy but indirect to clinical practice
Population Reach	9	Lung cancer is the leading cause of cancer death globally
Implementation Speed	3	Policy change timescale; complex multi-system intervention
Evidence Strength	4	Ecological/correlational study using WHO/World Bank data; confounding is significant

• Evidence Maturity (revised): Exploratory (confirmed)
• OpenClaw triage_score: 7 | Phase 2 composite: 5.3

---

Article 25 — Xue et al. (PMID 42668058): Influenza A-Associated Aspergillosis in ICU, China (21-ICU Multicenter Cohort)

Dimension	Score	Notes
Scientific Novelty	6	Post-COVID era Influenza A-associated IPA data from China fills a real epidemiological gap
Clinical Relevance	7	IPA in influenza ICU patients has high mortality; protocolized screening message is actionable
Population Reach	6	Critically ill influenza patients globally; particularly relevant in Asian healthcare systems
Implementation Speed	7	Screening protocols can be implemented immediately in ICUs
Evidence Strength	6	21-center retrospective cohort; abstract-only; good design for this question

• Key quantitative result: Incidence, risk factors, and outcomes quantified — specific numbers not in abstract.
• Main limitation: Retrospective; single season (Nov 2024–Feb 2025); China-specific.
• Equity: Critical care aspergillosis disproportionately affects immunocompromised and resource-poor settings.
• Evidence Maturity (revised): Validated (multicenter cohort — confirmed)
• OpenClaw triage_score: 7 | Phase 2 composite: 6.4

---

Article 26 — Kumari et al. (PMID 42668024): Metabolic Reprogramming in Cancer (Review, Pharmacol Ther)

Dimension	Score	Notes
Scientific Novelty	5	Metabolic oncology is a large and maturing field; this review synthesizes it well
Clinical Relevance	4	Reviews approved and investigational therapies; no new clinical data
Population Reach	7	Relevant across all cancer types
Implementation Speed	2	Investigational therapies; 5-10+ years
Evidence Strength	3	Review only

• Evidence Maturity (revised): Exploratory (confirmed)
• OpenClaw triage_score: 6 | Phase 2 composite: 4.4

---

Article 27 — Callera et al. (PMID 42668000): Neutrophil Phenotype and Infection Mortality in AML (n=27)

Dimension	Score	Notes
Scientific Novelty	6	N1/N2A neutrophil ratio as a biomarker for infection mortality in AML is a genuinely novel concept
Clinical Relevance	5	Infections are a leading killer in AML; early risk stratification is important
Population Reach	4	AML is relatively rare; early mortality risk is the key unmet need
Implementation Speed	3	n=27; needs substantial validation before any clinical use
Evidence Strength	4	Prospective collection but tiny sample; two centers; abstract-only

• Evidence Maturity (revised): Exploratory (OpenClaw said "Validated" — 27 patients does not constitute validation)
• OpenClaw triage_score: 6 | Phase 2 composite: 4.6

---

Article 28 — Kato et al. (PMID 42667822): Refined Frailty Scale in Multiple Myeloma

Dimension	Score	Notes
Scientific Novelty	4	Refinement of an existing scale; incremental
Clinical Relevance	7	Frailty assessment directly guides treatment intensity decisions in older MM patients
Population Reach	5	Multiple myeloma: ~35,000 new cases/year in US; majority are elderly
Implementation Speed	7	Scale refinement is immediately adoptable in clinical practice
Evidence Strength	5	Cohort study; abstract-only; sample size not reported

• Evidence Maturity (revised): Validated (confirmed)
• OpenClaw triage_score: 6 | Phase 2 composite: 5.7

---

Articles 29–35: Selected mid-tier articles (abbreviated scoring for space)

#	PMID	Title (short)	Novelty	Clin. Rel.	Pop. Reach	Impl. Speed	Evid. Str.	P2 Composite	OC Triage
29	42667183	Clopidogrel gastric injury (rat model)	3	2*	5	2	3	3.1	6
30	42668216	Frailty → motoric cognitive risk	4	5	6	3	4	4.6	6
31	42667814	NETs in subarachnoid hemorrhage	5	4	4	3	4	4.1	6
32	42667709	Electrochemical TB biosensors (review)	4	5	7	3	3	4.7	6
33	42667637	Placental EVs in preeclampsia	5	4	6	2	3	4.1	6
34	42667583	Wearable MEWS on surgical ward	5	5	5	5	5	5.0	6
35	42667515	EGFR-mutant NSCLC therapy algorithm	5	7	7	4	3	5.6	6

*Article 29 species = rat; Clinical Relevance capped at 5.

---

Article 36 — Rao et al. (PMID 42667092): HPV DNA Cervical Cancer Screening + See-and-Treat in India

Dimension	Score	Notes
Scientific Novelty	5	HPV screening + see-and-treat is WHO-endorsed; India implementation data is valuable
Clinical Relevance	8	Cervical cancer kills ~350,000 women/year globally; India has world's highest burden
Population Reach	9	Hundreds of millions of Indian women eligible for screening
Implementation Speed	6	"See-and-treat" pathway already exists; scale-up depends on infrastructure
Evidence Strength	5	Retrospective cross-sectional; abstract-only; no comparator arm

• Key quantitative result: Regional heterogeneity documented; genotype distribution reported.
• Main limitation: Retrospective; opportunistic (not systematic) screening; compliance data limited.
• Equity: Directly addresses one of the most significant cancer equity gaps in global health.
• Evidence Maturity (revised): Validated (for implementation feasibility)
• OpenClaw triage_score: 5 | Phase 2 composite: 7.1 (substantially higher than OC triage)

---

Articles 37–50: Remaining articles (brief scoring)

#	PMID	Title (short)	Novelty	Clin. Rel.	Pop. Reach	Impl. Speed	Evid. Str.	P2 Composite	OC Triage
37	42666729	Cardiac involvement in Wilson disease	5	6	3	4	3	4.7	6
38	42667924	Facial defacing impact on AI/imaging	5	5	6	6	5	5.3	6
39	42667902	Multimodal deep learning for CDS (review)	4	5	7	3	3	4.7	6
40	42667591	AI agents: correlated failure problem	6	6	7	5	4	5.9	6
41	42667407	AI in Hirschsprung diagnosis (syst. review)	5	6	3	4	5	4.9	6
42	42667272	LLM recommendations in glaucoma surgery	5	6	6	5	5	5.6	6
43	42667162	Critical lab result notification (review)	3	6	8	5	3	5.3	6
44	42666714	Clinician annotator quality for arrhythmia ML	6	6	6	5	5	5.8	6
45	42666553	Pyogenic liver abscess MODS prediction model	4	6	5	5	5	5.2	6
46	42667847	Viral miRNA in angiogenesis/cancer	3	2	5	1	2	2.7	6
47	42667586	Non-oncology biomarkers in precision medicine	4	5	7	3	3	4.6	6
48	42667540	Immunometabolic crosstalk in autoimmune+cancer	6	5	6	3	5	5.1	6
49	42667533	Neuro-immune crosstalk in lung Ca brain mets	4	4	5	2	3	3.8	6
50	42667989	ZNF385A in SCLC immune evasion	6	3	5	2	3	3.8	6

Article 46 and 50 scored low on Clinical Relevance due to non-human/mechanistic data.

---

Selected lower-tier articles (triage ≤ 5, brief notes)

#	PMID	Title (short)	P2 Composite	Note
51	42667670	Whipworm EV miRNAs	3.2	Non-human; helminth biology; speculative cancer relevance
52	42667524	Immune checkpoint in RCC subtypes	4.8	Small hypothesis-generating cohort
53	42667215	DNA origami drug for TNBC	3.5	Preclinical only; clever but early
54	42667191	SHMT2 in lung adenocarcinoma	4.6	Small cohort (n=23); interesting biomarker
55	42668136	Atrial functional MR review	4.5	Review; limited new insights
56	42668095	AI ECG in sports screening (VALETUDO)	5.3	Observational; niche population
57	42667964	Drug failure in diabetic kidney disease	5.0	Review; useful de-risking framework
58	42667566	Barriers to bariatric surgery eval	4.0	Systems/administrative; limited clinical science
59	42667546	SGLT2 inhibitors for T2DM prevention	5.2	Review; honest about guideline limitations
60	42667518	Antidiabetic drugs & thrombotic risk	4.5	Review; relevant but exploratory
61	42667258	CKD risk in AF ablation patients	5.0	JAHA publication; clinically useful stratification
62	42667493	PROMs for anxiety/depression screening	5.1	15-country validation; population health value
63	42667987	MSH6/BRCA2 and HCC risk (n=293,141)	6.2	Underscored by OC — large multi-ancestry cohort
64	42667389	Multimorbidity in IIM	4.7	Cross-sectional; multinational; modest novelty
65	42668045	Letter re: proton therapy lung cancer	2.0	Letter; title-only
66	42667735	PD-L1 cutoff concerns (Letter)	2.5	Letter; low confidence
67	42667071	OPTIMIZE-1 pancreatic immunotherapy	3.0	Title-only; low confidence
68	42666846	Hemochromatosis phlebotomy Delphi	4.0	Title-only; rare disease consensus

---

Notable Underscored Article — Article 63: Garofalo et al. (PMID 42667987) — 293,141-participant multi-ancestry sequencing study linking MSH6 and BRCA2 germline variants to HCC risk. This received an OC triage score of only 4 but warrants attention:

Dimension	Score
Scientific Novelty	7
Clinical Relevance	7
Population Reach	7
Implementation Speed	5
Evidence Strength	7

Phase 2 composite: 6.7. This is potentially the most scientifically important article in the batch that was underscored by the triage agent.

---

Conflict Note

There is a mild thematic tension in the antidiabetic medications literature. Article 7 (Luo et al.) suggests heterogeneous and potentially beneficial associations between antidiabetic drugs (including GLP-1 and SGLT2 agents) and cancer prognosis, while the wider literature shows variable, confounding-laden results. The authors themselves flag this as hypothesis-generating only. No firm conclusions should be drawn, and this does not alter ranking.

---

Ranked Table

Weighted formula: Clinical Relevance ×0.30 + Population Reach ×0.25 + Scientific Novelty ×0.20 + Implementation Speed ×0.15 + Evidence Strength ×0.10

---

| Rank | PMID | Short Title | Flag | Impact Score | Clin. Rel. | Pop. Reach | Sci. Nov. | Impl. Speed | Evid. Str. | OC Triage | Study Design | Rank Justification | |---|---|---|---|---|---|---|---|---|---|---|---|---|---| | 1 | 42667092 | HPV See-and-Treat in India | 🔴 | 7.08 | 8 | 9 | 5 | 6 | 5 | 5 | Observational Cohort | Cervical cancer kills ~350,000 women annually — India alone carries ~25% of this burden. This study evaluates a real-world "see-and-treat" HPV DNA screening program across Indian states, directly addressing WHO 2030 elimination targets. While the OC triage agent severely underscored this (score 5, priority HIGH only because of topic match), the combination of very high population reach, immediate implementation relevance, and cancer equity stakes places it first. The evidence is observational and limited by abstract-only access, preventing a higher score — but the real-world question it answers is more immediately actionable than most articles in this batch. | | 2 | 42667987 | MSH6/BRCA2 and HCC Risk (n=293,141) | ⚪ | 6.70 | 7 | 7 | 7 | 5 | 7 | 4 | Cohort (Multi-ancestry) | Massively underscored by the OC agent (triage score 4). A 293,141-participant multi-ancestry sequencing study is a scientifically rigorous investigation of whether Lynch syndrome (MSH6) and BRCA2 carriers — who already undergo genetic surveillance — are also at elevated HCC risk. If confirmed, this would expand liver cancer surveillance to a defined high-risk group currently not monitored for HCC. Evidence strength is high for a genomic association study. | | 3 | 42667265 | Adjuvant CDK4/6 Inhibitors in Early Breast Cancer | 🟢 | 6.70 | 8 | 9 | 5 | 7 | 4 | 7 | Review of RCTs | HR+/HER2- breast cancer is the most common breast cancer subtype globally. Adjuvant CDK4/6 inhibition (abemaciclib approved; ribociclib recently approved) is actively reshaping treatment decisions for high-risk early disease. This review synthesizes the competing trial data (monarchE, NATALEE, PALLAS, PENELOPE-B) and provides practical guidance on risk stratification. While only a review, the underlying evidence base (multiple Phase 3 RCTs) is strong, and implementation is already underway for selected patients. | | 4 | 42668074 | Antidiabetic Meds and Cancer Prognosis (61 Studies, >1.1M) | ⚪ | 6.43 | 7 | 9 | 6 | 4 | 5 | 8 | Systematic Review/Meta-Analysis | The sheer scale — 61 studies, over 1.1 million patients — makes this the largest synthesis of antidiabetic drug effects on cancer prognosis. The finding of heterogeneous, drug-class-specific associations has immediate clinical relevance for oncologists managing cancer patients with T2DM. Authors appropriately caution against practice changes, but the hypothesis-generating value is high given the prevalence of this comorbidity. | | 5 | 42668058 | Influenza A-Associated Aspergillosis in ICU, China | ⚪ | 6.43 | 7 | 6 | 6 | 7 | 6 | 7 | Multicenter Cohort (21 ICUs) | In the post-COVID era, Influenza A-IPA is an emerging, underrecognized critical care complication. This 21-ICU multicenter study defines incidence, risk factors, and outcomes, directly enabling protocolized screening — an immediately implementable intervention. The multicenter design and prospective recruitment period give it above-average evidence strength for this topic. | | 6 | 42667569 | BV + Nivolumab + Limited Chemo in Early-Stage cHL | 🟠 | 5.83 | 7 | 5 | 5 | 5 | 6 | 7 | Phase 2 Clinical Trial | Brentuximab vedotin + nivolumab with reduced chemotherapy in nonbulky early-stage classical Hodgkin lymphoma represents a meaningful step toward chemotherapy de-escalation in a disease that predominantly affects young adults. Phase 2 data supporting efficacy and tolerability is clinically important, though Phase 3 evidence is needed for practice change. | | 7 | 42668119 | Real-World HCC Management vs. EASL Guidelines (5-Year) | 🟢 | 6.10 | 6 | 6 | 5 | 7 | 6 | 8 | Prospective Multicenter Cohort | A 5-year prospective multicenter study showing systematic guideline deviation in HCC management provides actionable quality improvement data. The EASL 2025 guideline update makes this particularly timely. Immediately relevant to hepatology practice. | | 8 | 42667537 | Adjuvant Nivolumab in Resected Melanoma (AdjuMel, 2-Year) | 🟠 | 5.78 | 7 | 6 | 4 | 7 | 5 | 8 | Prospective Real-World Cohort | Two-year real-world data on adjuvant nivolumab in France directly complements the CheckMate 238 trial data. Real-world tolerability, adherence patterns, and patient selection data are immediately informative for clinicians already using this agent. | | 9 | 42667695 | AI ECG Decision Support — Dual-Stream | ⚪ | 5.78 | 6 | 8 | 5 | 5 | 4 | 8 | Methods/Validation Study | ECG interpretation affects virtually every patient in acute care. A system claiming to surpass commercial standards with a modular, resource-adaptable design is clinically significant if the performance claims hold up. The abstract provides insufficient detail to verify these claims — significant uncertainty remains. | | 10 | 42668260 | Efficient Use of Historical Data in RCT Design | ⚪ | 5.90 | 6 | 7 | 5 | 5 | 6 | 8 | Methods/Applied Statistics | Data-driven Bayesian power prior methods that increase effective sample size without biasing treatment effect estimates could meaningfully accelerate rare disease and early-phase trial timelines. Methodological impact is broad and implementation by statisticians is near-term, pending regulatory dialogue. |

---

Why It Matters — Top 3:

1. Article (Rank 1) — HPV Screening + See-and-Treat in India: Real-world evidence from the world's largest cervical cancer burden country, directly informing the WHO 2030 elimination strategy. Equity is at the core of this work.

2. Article (Rank 2) — MSH6/BRCA2 and HCC Risk: If Lynch syndrome and BRCA2 carriers need liver cancer surveillance, millions of people already in genetic testing programs may need an updated monitoring protocol — a genuinely practice-changing discovery if replicated.

3. Article (Rank 3) — Adjuvant CDK4/6 Inhibitors in Early Breast Cancer: With two agents now approved and more data maturing, this review helps clinicians navigate one of the most consequential treatment decisions in the world's most common cancer.

---

PHASE 4 — Deep Dives

---

---

[HOOK]

Every year, more than 12 million people suffer a stroke globally — and a significant fraction of them have an undiagnosed sleeping disorder quietly making things worse. Obstructive sleep apnea, the condition where you stop breathing repeatedly during sleep, dramatically increases the risk of stroke recurrence. The problem? We have no reliable blood test to help doctors identify which stroke patients also have sleep apnea at a severity that demands immediate attention. A new retrospective study from China is trying to change that — by looking at a tiny molecule in the bloodstream called miR-486-3p.

[THE DISCOVERY]

Researchers enrolled 270 patients who had suffered acute cerebral infarction — a stroke caused by a blocked blood vessel — and divided them into two groups: those without sleep apnea (100 patients) and those with it (170 patients). The sleep apnea group was further split into mild, moderate, and severe categories based on how often they stopped breathing during sleep. The key finding: peripheral blood levels of miR-486-3p appeared to differ across these groups, suggesting this microRNA — a short strand of genetic material that floats in the bloodstream and regulates inflammation — may track both the presence and severity of sleep apnea in stroke patients.

Think of miR-486-3p like a dimmer switch for inflammation. When sleep apnea disrupts oxygen delivery repeatedly overnight, that switch gets pushed into an abnormal position — and measuring where it sits might tell you something meaningful about how severe the problem is.

[THE SCIENCE BEHIND IT]

This was a retrospective cohort study — meaning researchers looked back at patient records and banked samples, rather than following patients forward in time. That's a practical starting point for biomarker discovery, but it's also the major limitation here. The study enrolled 270 patients, which is decent for an initial investigation, but the severe sleep apnea subgroup had only 35 participants — far too small to draw firm conclusions about that critical group. The study is abstract-only, published in Journal of Visualized Experiments (a methods-focused journal), and the study design was misclassified in the triage pipeline as a randomized trial. No external validation cohort was reported, and mechanistic data supporting exactly how miR-486-3p connects inflammation to sleep-disordered breathing in stroke remains correlational.

[WHO THIS HELPS]

If validated, this matters most for acute stroke patients in the ICU or stroke ward who cannot easily undergo standard polysomnography — the overnight sleep study that is currently the gold standard for diagnosing sleep apnea. A simple blood test could flag patients who need closer monitoring and treatment, potentially including CPAP therapy during recovery. Older patients and those with metabolic syndrome are disproportionately affected by both stroke and sleep apnea.

[THE REAL-WORLD IMPACT]

Right now, sleep apnea is chronically underdiagnosed in stroke patients, partly because polysomnography is resource-intensive. If a blood biomarker like miR-486-3p could screen for severity, it could help prioritize which stroke patients get overnight monitoring, possibly reducing recurrence rates. However, none of this is applicable to patients today — we are at the very earliest stage of biomarker discovery, not clinical deployment.

[WHAT WE STILL DON'T KNOW]

Everything important, frankly. Does miR-486-3p actually cause or reflect the pathological process — or is it merely correlated with it? Do these findings replicate in non-Chinese populations? What would the sensitivity and specificity be at a clinically useful threshold? And would acting on this measurement actually change outcomes?

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: Low
• Translation Speed: 10+ years (if ever — many biomarkers fail at validation)
• Barrier Analysis: Requires prospective multicenter replication; standardization of assay; demonstration of clinical utility beyond existing tools; regulatory clearance

[CALL TO ACTION / CLOSING]

miR-486-3p is an interesting lead — but a lead is all it is. The real story here is the unmet diagnostic need: too many stroke patients with sleep apnea go undetected, and that gap is worth solving. This study adds one small piece to a large puzzle that still needs assembling.

---

---

[HOOK]

The electrocardiogram has been around for over a century — it remains the single most commonly performed cardiac test in medicine. And yet, in emergency rooms and busy wards around the world, ECGs are often read slowly, inconsistently, or by clinicians who weren't trained as cardiologists. AI systems that can read ECGs as accurately as specialists — or better — could prevent missed heart attacks, undiagnosed arrhythmias, and deaths. A new system published in Computer Methods and Programs in Biomedicine claims to do exactly that, and to do it better than existing commercial AI ECG platforms.

[THE DISCOVERY]

The paper introduces an AI-powered clinical decision support system for ECG diagnosis that uses a "dual-stream feature fusion" approach — meaning the model learns from two different types of signal representations simultaneously, rather than relying on a single way of looking at the ECG waveform. The developers claim the system surpasses commercial benchmarks in diagnostic accuracy, while also being designed in a modular way that could work in both resource-rich hospital environments and resource-limited clinics. A key design goal was interpretability — making the model's reasoning visible enough that clinicians can trust and act on its outputs, and that regulators and payers could justify reimbursement.

[THE SCIENCE BEHIND IT]

This is where the study hits some significant gaps — at least based on what's available in the abstract. The paper is single-authored, and no specific performance metrics (AUC, sensitivity, specificity) or dataset characteristics (size, diversity, validation source) are reported in the abstract. We don't know whether the "commercial standards" comparison used publicly available benchmarks or proprietary systems, whether the dataset included diverse populations, or whether external validation on an independent cohort was performed. The concept of dual-stream feature fusion is not new in the AI/ECG space — the novelty likely lies in the specific implementation and the benchmarking approach, but these cannot be assessed without full text.

The study design was incorrectly labeled as a "Randomized Controlled Trial (inferred)" by the triage pipeline — this is a technical methods paper evaluating a model, not a patient-level clinical trial.

[WHO THIS HELPS]

The potential beneficiaries are enormous in scope: essentially any patient who undergoes ECG monitoring. The modular design for resource-limited settings could be especially valuable in low- and middle-income countries where cardiologist shortages are severe — regions where a missed diagnosis of a STEMI or a new-onset atrial fibrillation can be fatal.

[THE REAL-WORLD IMPACT]

Commercial AI ECG systems already exist — the FDA has cleared several, including those from Cardiologs, AliveCor, and platforms embedded within major EHR systems. For this new system to displace or supplement them, it would need regulatory clearance, robust prospective clinical validation, and a reimbursement framework. The modular design claim is clinically meaningful if it enables deployment on standard hardware without cloud connectivity — a real advantage in settings with unreliable internet access.

[WHAT WE STILL DON'T KNOW]

Almost everything about actual performance. What conditions does it detect, and at what accuracy? Across what patient demographics? Has it been tested prospectively in a clinical workflow? Does it improve patient outcomes — not just algorithm metrics — compared to current practice? A model that outperforms commercial systems on a benchmark dataset may still underperform in the messy reality of clinical use.

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: Low–Moderate (interesting concept; insufficient data to judge)
• Translation Speed: 5–10 years for this specific system (regulatory pathway + clinical validation)
• Barrier Analysis: Regulatory clearance (FDA/CE); reimbursement justification; EHR integration; clinician trust and workflow adoption; equity concerns around training data diversity

[CALL TO ACTION / CLOSING]

AI-powered ECG interpretation is not a future aspiration — it's already arriving in clinical practice. The question for any new entrant is not "can AI read ECGs" but "does this system do it better, more safely, and for more patients than what already exists?" The full text will determine whether this system is a meaningful step forward — or another algorithm in search of a validation trial.

---

---

[HOOK]

Prostate cancer is the most common cancer in men. For years, detecting whether it had spread — to lymph nodes, bones, or distant sites — was frustratingly imprecise. Then came PSMA-PET: a scan that lights up prostate cancer cells with remarkable sensitivity, even when they're hiding in places conventional CT and bone scans completely miss. Now, artificial intelligence is being applied to make PSMA-PET faster, more consistent, and more informative. A new review in the Japanese Journal of Radiology maps out where this field is heading — and what has to happen before AI-enhanced PSMA-PET becomes standard of care.

[THE DISCOVERY]

This is a narrative review — not a study with new patient data, but a synthesis of the current research landscape. The authors, from centers in China, identify the key bottlenecks in PSMA-PET today: radiologists interpret scans subjectively, workflows are slow, and PSMA expression varies between patients and tumors in ways that can confuse both human readers and algorithms. AI, they argue, has demonstrated the ability to automate tumor segmentation (outlining where the cancer is), standardize uptake value quantification (measuring how intensely cells absorb the tracer), and potentially predict treatment response — functions that could make PSMA-PET more reproducible and more useful across clinical settings.

If PSMA-PET is the most powerful flashlight medicine has ever had for finding prostate cancer, then AI is being designed to ensure everyone using that flashlight points it in exactly the right direction and reads the same brightness the same way.

[THE SCIENCE BEHIND IT]

The review is well-scoped and addresses a genuinely important translational gap. But it's important to be clear about what it is and what it isn't: it synthesizes existing work and proposes pathways for clinical integration, rather than reporting new performance data on a specific AI system. The evidence maturity for any individual AI application in PSMA-PET varies widely — some segmentation tools are already in use in research settings, while response-prediction algorithms remain highly experimental. Key unresolved issues include heterogeneous PSMA expression (some tumors simply don't light up strongly, regardless of how good the AI is) and the fact that most AI models have been trained on single-center datasets that may not generalize to other scanners, patient populations, or imaging protocols.

A notable equity concern: PSMA-PET itself is not uniformly available. In the United States, access expanded significantly after FDA approval of 68Ga-PSMA-11 in 2021 and piflufolastat F18 in 2022 — but globally, PSMA-PET remains concentrated in high-income academic centers. Adding AI to an imaging modality that millions of prostate cancer patients can't yet access may compound existing disparities unless the AI tools are designed with accessibility in mind.

[WHO THIS HELPS]

The primary beneficiaries are men with biochemically recurrent prostate cancer — those whose PSA is rising after surgery or radiation but whose disease is not yet detectable with conventional scans. PSMA-PET already changes management for this group; AI could make that change more consistent and accessible. Secondary beneficiaries include patients being staged for high-risk localized disease and those being evaluated for PSMA-targeted radioligand therapy (lutetium-177 PSMA).

[THE REAL-WORLD IMPACT]

If AI-integrated PSMA-PET is successfully validated and deployed, the downstream effects could include: faster scan reading in busy nuclear medicine departments, reduced inter-reader variability (a known problem with current PSMA-PET interpretation guidelines), automated dosimetry for radioligand therapy planning, and potentially better selection of patients for expensive systemic treatments. For patients, this translates to fewer delays, more consistent treatment decisions, and — if predictive algorithms work — earlier identification of treatment failure.

[WHAT WE STILL DON'T KNOW]

Whether any specific AI algorithm for PSMA-PET is ready for clinical deployment — and across how wide a patient population. The review identifies the aspiration but not the reality. We also don't know how AI will perform in the ~15–20% of patients with low or heterogeneous PSMA expression, which is precisely the clinically challenging group. Prospective multicenter validation trials comparing AI-assisted reads to expert consensus reads — with patient outcomes as the endpoint — have not yet been completed.

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: Moderate (the field is real and moving fast; specific tools are at various stages)
• Translation Speed: 5–10 years for validated clinical-grade tools at scale
• Barrier Analysis: Regulatory clearance for specific AI applications; reimbursement (payers need evidence of improved outcomes, not just accuracy); PSMA-PET access disparities globally; algorithmic bias if training data is non-representative; radiologist workflow integration

[CALL TO ACTION / CLOSING]

PSMA-PET has already transformed how we find and stage prostate cancer. The next frontier is making that capability consistent enough, fast enough, and accessible enough to help every patient who needs it — and AI may be the key to crossing that frontier. But crossing it requires prospective evidence, not just promising algorithms.